Extending the COVID-19 Data Platform
As the COVID-19 Data Platform expands, it has enabled our partners to build useful infectious disease tools and services on top of it.
EMBL has acted swiftly in response to COVID-19 by launching new initiatives and re-purposing existing facilities to provide a range of direct research and support services, including in collaboration with institutes in the Member States.
Image credit: Aleksandra Krolik/EMBL
Our scientists and collaborators discuss how EMBL's state-of-the-art facilities, expertise and service provisions have helped the global community tackle COVID-19.
As the COVID-19 Data Platform expands, it has enabled our partners to build useful infectious disease tools and services on top of it.
In a race against time, researchers at QBI UCSF, Institut Pasteur, University of Freiburg and EMBL-EBI combined their expertise to identify drugs to stop SARS-CoV-2 from infecting cells.
Ralf Bartenschlager from the University of Heidelberg discusses how he utilised EMBL's expertise and the Electron Microscopy Core Facility to study how SARS-CoV-2 highjacks human cells.
Researchers from Karolinska Institutet in Stockholm, EMBL Hamburg and the Centre for Structural Systems Biology (CSSB) in Hamburg teamed up to screen hundreds of synthetic mini-antibodies called sybodies, the scientists identified one that might stop SARS-CoV-2 from infecting human cells.
As part of the COVID-19 Data Platform, a number of national portals have launched across Europe focusing on COVID-19 research and data sharing.
Gerhard Hummer and Martin Beck from the Max Planck Institute of Biophysics and Jacomina Krijnse Locker from the Paul Ehrlich Institute describe the insights gained on the COVID-19 spike protein and how EMBL’s expertise and infrastructure was essential for their work.
“We would not have progressed as fast without the imaging facility of EMBL.”
- Prof. Dr. Jacomina Krijnse Locker from the Paul Ehrlich Institute
The COVID-19 Data Portal enables researchers to upload, access and analyse COVID-19 related reference data and specialist datasets as part of the wider European COVID-19 Data Platform.
RBPbase is a database of over 4000 RNA-binding proteins (RBPs) to assist researchers worldwide in the identification of proteins that interact with the SARS-CoV-2 RNA genome.
Dedicated pages that highlight important structural features of the SARS-CoV-2 virus, including all observed ligand binding sites and protein-protein interaction residues, to support researchers in the development of treatments and vaccines.
The latest available pre-release UniProtKB data for the SARS-CoV-2 coronavirus.
The complete genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) isolate.
Integration of key datasets to identify and prioritise potential human and viral protein drug targets for COVID-19 treatments.
Latest scientific publications and grants available in a single repository.
A summary of SARS-CoV-2 related bioactive molecules.
EMBL continues to provide many of our services in virtual and remote formats, to support research efforts efficiently and effectively during the pandemic.
EMBL Grenoble’s fully automated protein- to-structure pipeline is available for external users and can be accessed via a mail-in sample service.
The Sample Preparation and Characterisation Facility at EMBL Hamburg is open to support scientists working on COVID-19 research. our programme to scientists virtually all over the globe.
EMBL researchers are using small-angle X-ray scattering to study the structure and interaction of SARS-CoV-2 molecules.
To study how SARS-CoV-2 infects cells, researchers in the Gene Editing and Embryology Facility (GEEF) at EMBL Rome are working on a transgenic mouse line, which has the potential to advance antibody and vaccine preclinical trials.
EMBL Grenoble and ESRF offer SARS-CoV-2 related projects combined access to the JSBG beamlines and to the HTX Lab services through a single project proposal.
EMBL continues to provide many of our training offerings, courses and conferences in virtual and remote formats, to continue to train and inspire the next scientific generation.
EMBL-EBI training enables scientists at all levels to get the most out of publicly available biological data, and continues to train scientists virtually.
EMBL has been training scientists since 1977, and continues that tradition in 2020 bringing our programme to scientists virtually all over the globe.
The European Learning Laboratory for the Life Sciences (ELLS) – EMBL’s education facility – offers virtual guided tours of EMBL for school groups.
EMBL’s efforts to fight COVID-19